China High Quality 5a-Hydroxy Laxogenin Factory – 99% Apixaban CAS 503612-47-3 – Baoran

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Our organization has been focusing on brand strategy. Customers' gratification is our greatest advertising. We also source OEM provider for P-Aminophenol, Pivalic Acid, Hydroquinone, As a key enterprise of this industry, our corporation makes attempts to become a leading supplier, depending on the faith of expert excellent & throughout the world assistance.
China High Quality 5a-Hydroxy Laxogenin Factory – 99% Apixaban CAS 503612-47-3 – Baoran Detail:

Specification

ITEM

STANDARD

Appearance

White to off-white solid

Purity

≥ 99%

Application

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a joint development of the new oral anticoagulant apixaban owned by Bristol-Myers Squibb as an upgraded alternative to warfarin.
In May 2011, apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in 27 EU countries, Iceland and Norway.
On November 20, 2012, the European Commission approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
The Canadian Food and Drug Administration, Japan, and the U.S. Food and Drug Administration subsequently approved ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors.
On April 12, 2013, ELIQUIS (Apixaban), was officially announced on the market in China. Apixaban is a novel oral factor Xa inhibitor for the prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its launch provides a safe and effective new option for anticoagulation after orthopaedic surgery in clinical practice, and brings good news to Chinese patients undergoing elective hip/knee replacement.
Clinical studies have confirmed that compared with 40 mg subcutaneous injection of enoxaparin once a day, 2.5 mg of ELIQUIS (Apixaban) orally twice a day is more effective in preventing venous thromboembolic events after hip or knee replacement surgery , and does not increase the risk of bleeding.

Packing & Storage

100g/500g/1kg/25kg or as request;
Stored at room temperature and airtight.


Product detail pictures:

China High Quality 5a-Hydroxy Laxogenin Factory –  99% Apixaban CAS 503612-47-3 – Baoran detail pictures


Related Product Guide:

Using a complete scientific high quality management program, superior high quality and superior faith, we acquire great reputation and occupied this industry for China High Quality 5a-Hydroxy Laxogenin Factory – 99% Apixaban CAS 503612-47-3 – Baoran, The product will supply to all over the world, such as: Surabaya, Italy, Guyana, We believe that good business relationships will lead to mutual benefits and improvement for both parties. We now have established long-term and successful cooperative relationships with many customers through their confidence in our customized services and integrity in doing business. We also enjoy a high reputation through our good performance. Better performance will be expected as our principle of integrity. Devotion and Steadiness will remain as ever.
  • High production efficiency and good product quality, fast delivery and completed after-sale protection, a right choice, a best choice.
    5 Stars By Ivy from Nepal - 2018.02.12 14:52
    The customer service staff's attitude is very sincere and the reply is timely and very detailed, this is very helpful for our deal,thank you.
    5 Stars By Liz from Greek - 2018.11.28 16:25
    Write your message here and send it to us

    Related Products